Here are 1-3 brief analogies for Amesite (AMST):

• An AI-powered Blackboard or Canvas for educational institutions and businesses.
• Like Netflix for personalized online education and professional training.

• AI-powered Learning Platform: An artificial intelligence-driven technology platform that uses machine learning to deliver a mass customized online learning experience.
• Online Course Design and Delivery: Services focused on designing, developing, and providing online educational courses for businesses, universities, K-12 schools, and non-profit organizations.

Amesite Inc. (AMST) primarily sells its artificial intelligence-driven online learning platforms and course design services to other organizations rather than directly to individuals. Its major customers fall within the categories of businesses, universities and colleges, K-12 schools, and non-profit organizations.

Based on publicly available information and company announcements, some of Amesite's notable customers include:

• City University of New York (CUNY): A large public university system.
• Wayne State University: A public research university.
• Michigan State University: A public research university.
• The World Academy of Sport (WAoS): An international organization providing education for sports professionals.
• National Association for Black Veterans (NABVETS): A non-profit organization.

None of these identified major customers are public companies with stock symbols.

Ann Marie Sastry, Founder, CEO, and Chair, Amesite Inc. Board of Directors

Dr. Ann Marie Sastry is the founder, CEO, and Chair of the Board of Directors for Amesite Inc.. She previously founded and served as CEO and co-Founder of Sakti3, a company that was acquired by Dyson in 2015 for $90 million. Prior to her entrepreneurial ventures, Dr. Sastry served as an Arthur F. Thurnau Professor at the University of Michigan for 17 years.

Sarah Berman, Principal Financial and Accounting Officer

Sarah Berman serves as the Principal Financial and Accounting Officer at Amesite, a role she assumed effective December 15, 2024. She is a Certified Public Accountant (CPA) and founded her own accounting advisory firm, Better Books Consulting, in June 2019. Her prior experience includes positions as Senior Accountant at Big Red's Equipment and Senior Audit Manager at Turner, Stone & Company, L.L.P..

Brandon Owens, Vice President of Sales

Brandon Owens is the Vice President of Sales at Amesite, where he contributes his extensive experience in sales leadership, technology, and business. He is responsible for leading Amesite's NurseMagic enterprise sales efforts.

J. Michael Losh, Board Member

J. Michael Losh has been a member of Amesite's board of directors since February 2018. He previously held the position of Chief Financial Officer at Cardinal Health from July 2004 to May 2005. Before that, Mr. Losh was with General Motors from 1964 to 2000, serving as Chief Financial Officer and Executive Vice President from July 1994 to August 2000.

Gilbert Omenn, Board Member

Gilbert Omenn has served as a member of Amesite's board of directors since March 2020, having previously been on its board of advisors. He is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. Dr. Omenn brings decades of public-company board experience, including 27 years with Amgen, Inc. and 22 years with Rohm & Haas Company. He also served as Dean of the University of Washington School of Public Health & Community Medicine (1982-1997) and Executive Vice President for Medical Affairs at the University of Michigan and CEO of the UM Health System (1997-2002).

The key risks for Amesite (AMST) are primarily centered around its financial viability, intense market competition, and the inherent challenges associated with developing and deploying AI-driven platforms in sensitive sectors.

1. Financial Instability and Going Concern Risk: Amesite has a history of losses and a substantial need for additional funding to continue its operations, with uncertainty about achieving or sustaining profitability in the future. The company's operations have consumed significant amounts of cash since its inception, and it currently has less than a year of cash runway based on its current free cash flow. Recent financial reports indicate high operating expenses that exceed revenues, leading to ongoing deficits. Furthermore, Amesite has received a notice from the Nasdaq Stock Market LLC regarding non-compliance with certain continued listing standards, specifically related to stockholders' equity, highlighting a significant financial and regulatory challenge.
2. Competition and Market Adoption: Amesite operates in a highly competitive industry, requiring continuous adaptation to regulatory changes, maintaining differentiation, and building trust within the evolving AI landscape. The company's success heavily depends on the sustained adoption of its AI-powered products, such as NurseMagic™. Despite a pivot towards the healthcare market with NurseMagic™, the need to gain significant market traction and differentiate itself amidst existing and emerging competitors remains a critical challenge for revenue growth and long-term viability.
3. Data Privacy, Algorithmic Bias, and Regulatory Compliance: As a developer of AI platforms for education and healthcare, Amesite handles vast datasets, often including sensitive personal information about students and patients. This creates significant risks related to data privacy and security, including potential data breaches, identity theft, unauthorized profiling, and commercial exploitation of data by third parties. The company also faces challenges regarding algorithmic bias, where biased training data can perpetuate and exacerbate existing inequalities, potentially leading to discriminatory practices. Ensuring robust cybersecurity measures against threats like model inversion attacks and prompt injection vulnerabilities, along with continuous adherence to evolving regulatory compliance, such as HIPAA for its NurseMagic™ platform, is crucial to avoid legal issues, maintain user trust, and mitigate reputational damage.

The rapid integration of advanced artificial intelligence, particularly generative AI and personalized learning engines, into widely adopted existing learning management systems (LMS) by their primary vendors. These vendors already serve Amesite's target customers (businesses, universities, K-12 schools, and non-profit organizations) and could develop or acquire capabilities that replicate or surpass Amesite's "mass customized experience" within their established platforms, thereby diminishing the need for a specialized third-party provider.

Amesite Inc. (NASDAQ: AMST) operates in several significant addressable markets within the United States, leveraging its artificial intelligence-driven platform and course design capabilities for various sectors, and its AI-powered NurseMagic™ platform for healthcare.

AI in Education Platforms

• The U.S. AI-driven education platform market is projected to be valued at approximately $2.3 billion in 2025, with an expected growth to $24.8 billion by 2034.
• More broadly, the U.S. AI in Education market was valued at $3.16 billion in 2024 and is anticipated to reach $24.20 billion by 2032.

Online Learning and E-Learning Market (U.S.)

• The overall U.S. e-learning market exceeded $128.37 billion in 2024 and is projected to grow to $278.27 billion by 2033. Another estimate places the U.S. e-learning market size at $145.52 billion in 2025, reaching $302.18 billion by 2034.
• Corporate E-learning: The U.S. corporate e-learning market generated a revenue of $25.46 billion in 2024 and is expected to reach $67.61 billion by 2030.
• K-12 Online Education: The U.S. online K-12 education market size is estimated to reach $74 billion by 2030.
• Higher Education Online Learning: The online higher education market in the U.S. represents over $20 billion currently, with more than three million students pursuing higher education fully online. The U.S. higher education technology market is expected to reach a projected revenue of $19.59 billion by 2030.

NurseMagic™ for Healthcare

• Amesite is targeting the substantial U.S. healthcare market. This includes 16,700 Skilled Nursing and Home Health Care Facilities employing 1.38 million workers, and 8,514 hospice organizations with 407,692 workers.
• The U.S. Home Healthcare Market size is valued at over $130 billion.

Amesite Inc. (AMST) is positioned for future revenue growth over the next 2-3 years, primarily driven by the ongoing expansion and enhancement of its AI-powered NurseMagic™ platform within the healthcare sector. Key drivers include:

1. Accelerated adoption and growth of NurseMagic™ across the home and post-acute healthcare segments: Amesite has shifted its primary focus to the home and healthcare markets with its NurseMagic™ app, which streamlines documentation for nurses and caregivers. The company has reported significant growth in contracts with hospice providers and an increase in contract sizes, reflecting strong customer demand and market penetration in these segments. This includes both Business-to-Business (B2B) enterprise sales and Business-to-Consumer (B2C) sales.

2. Launch and increasing uptake of the AI-native NurseMagic™ Electronic Medical Record (EMR): Introduced in December 2025, the AI-native NurseMagic™ EMR expands the platform from a point-of-care tool to a core infrastructure solution for post-acute care. Customer onboarding for the EMR began in January 2026, which is expected to significantly accelerate enterprise sales momentum by offering flexible deployment options, including coexistence with legacy systems or full replacement.

3. Introduction of AI-powered automation tools, such as government form-fill automation: Amesite launched AI-powered automated form-fill capabilities in September 2025, specifically designed to reduce the administrative burden associated with required government forms. This feature aims to help post-acute care providers, particularly with mandates like the Hospice Outcomes and Patient Evaluation (HOPE) assessment, ensuring compliant and reimbursable documentation and attracting more enterprise clients.

4. Successful rollout of higher-value product tiers and continuous platform enhancements: The company has demonstrated a clear strategy of introducing progressively higher-value product tiers, such as Teams+ (May 2025) and the census-based Enterprise tier (July 2025). These launches have consistently led to substantial quarter-over-quarter revenue increases, indicating a successful model for expanding offerings and monetizing increased customer engagement and usage.

Share Repurchases

Amesite Inc. has not reported any share repurchase programs or activities during the last 3-5 years (fiscal years ended June 30, 2021, 2022, 2023, 2024, and 2025).

Share Issuance

• On January 8, 2025, Amesite Inc. closed a public offering, issuing 1,201,667 shares of common stock at $3.00 per share, raising approximately $3.6 million in aggregate.
• In the fiscal year ended June 30, 2024, the company reported the issuance of common stock, net of issuance costs, totaling $1,850,503.
• During the fiscal year ended June 30, 2025, the company issued common stock for consulting services, amounting to $654,975 for 250,000 shares, and warrants for an underwriting fee of $95,984.
• Throughout 2025 and early 2026, Amesite directors converted Restricted Stock Units (RSUs) into common shares as part of their equity compensation. For example, on March 7, 2026, director Parmer George converted 41,322 RSUs into common shares, and a trust associated with director J. Michael Losh converted 41,322 RSUs into common stock.

Inbound Investments

There is no public information indicating large strategic investments made in Amesite Inc. by third-party strategic partners or private equity firms within the last 3-5 years. While various institutional investors hold shares in Amesite, these typically represent open-market purchases rather than direct company-level investments.

Outbound Investments

Amesite Inc. has not disclosed any instances where the company made strategic investments in other companies during the past 3-5 years.

Capital Expenditures

• For the fiscal year ended June 30, 2025, capital expenditures for the purchase of property and equipment amounted to $38,000.
• For the fiscal year ended June 30, 2024, capital expenditures for the purchase of property and equipment were $38,000.
• For the fiscal year ended June 30, 2023, capital expenditures for the purchase of property and equipment totaled $40,000.
• The company indicated that proceeds from the January 2025 public offering would be used for general corporate purposes, including capital expenditures, working capital, and general and administrative expenses.